Clinical Trials Browser

Completed × brigatinib × Lymphoid × Clear all

NCT01449461 2021-08-17

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Phase 1/2 Completed

137 enrolled 38 charts

LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Large-Cell, Anaplastic